May Hagiwara

1.5k total citations
51 papers, 1.2k citations indexed

About

May Hagiwara is a scholar working on Pulmonary and Respiratory Medicine, Hematology and Oncology. According to data from OpenAlex, May Hagiwara has authored 51 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Hematology and 12 papers in Oncology. Recurrent topics in May Hagiwara's work include Asthma and respiratory diseases (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Cancer Diagnosis and Treatment (7 papers). May Hagiwara is often cited by papers focused on Asthma and respiratory diseases (8 papers), Multiple Myeloma Research and Treatments (7 papers) and Cancer Diagnosis and Treatment (7 papers). May Hagiwara collaborates with scholars based in United States, Switzerland and India. May Hagiwara's co-authors include Gerry Oster, Thomas E. Delea, Montserrat Vera‐Llonch, Stephen T. Sonis, John Edelsberg, Karen Chung, Lawrence S. Phillips, Richard H. Stanford, Pradyumna D. Phatak and David A. Stempel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

May Hagiwara

50 papers receiving 1.2k citations

Peers

May Hagiwara
Mark Krasnik Denmark
Sheena Patel United States
Kelly W. Merriman United States
J. Green United Kingdom
C McLeod United Kingdom
L M Forrest United Kingdom
Beatriz Korc‐Grodzicki United States
Jonas Lundkvist Sweden
Young Eun Kwon South Korea
David R. Stather Canada
Mark Krasnik Denmark
May Hagiwara
Citations per year, relative to May Hagiwara May Hagiwara (= 1×) peers Mark Krasnik

Countries citing papers authored by May Hagiwara

Since Specialization
Citations

This map shows the geographic impact of May Hagiwara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by May Hagiwara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites May Hagiwara more than expected).

Fields of papers citing papers by May Hagiwara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by May Hagiwara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by May Hagiwara. The network helps show where May Hagiwara may publish in the future.

Co-authorship network of co-authors of May Hagiwara

This figure shows the co-authorship network connecting the top 25 collaborators of May Hagiwara. A scholar is included among the top collaborators of May Hagiwara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with May Hagiwara. May Hagiwara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Tiffany, et al.. (2023). Liver disease progression in patients with alpha‐1 antitrypsin deficiency and protease inhibitor ZZ genotype with or without lung disease. Alimentary Pharmacology & Therapeutics. 58(10). 1075–1085. 5 indexed citations
2.
Fonseca, Rafaël, May Hagiwara, Sumeet Panjabi, et al.. (2021). Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. Blood Cancer Journal. 11(2). 35–35. 4 indexed citations
3.
Ma, Qiufei, Thomas E. Delea, May Hagiwara, et al.. (2021). Lifetime Costs for Treated Follicular Lymphoma Patients in the US. PharmacoEconomics. 39(10). 1163–1183. 3 indexed citations
4.
Hagiwara, May, et al.. (2016). Retrospective study of frequency and cost of multiple myeloma (MM) complications and treatment (Tx) related adverse events (AEs).. Journal of Clinical Oncology. 34(15_suppl). 8060–8060. 2 indexed citations
5.
6.
Weycker, Derek, et al.. (2015). Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?. Supportive Care in Cancer. 24(5). 2309–2316. 41 indexed citations
7.
Hagiwara, May, Thomas E. Delea, & Karen Chung. (2014). Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases. Journal of Medical Economics. 17(3). 223–230. 25 indexed citations
8.
Hagiwara, May, Thomas E. Delea, Ze Cong, & Karen Chung. (2013). Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Supportive Care in Cancer. 22(1). 103–113. 20 indexed citations
9.
10.
Hagiwara, May, Thomas E. Delea, M. Wayne Saville, & Karen Chung. (2012). Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer and Prostatic Diseases. 16(1). 23–27. 52 indexed citations
11.
Hagiwara, May, Thomas E. Delea, & Richard H. Stanford. (2011). Retrospective Comparison of Early versus Late Treatment with Fluticasone Propionate/Salmeterol After an Asthma Exacerbation. Journal of Asthma. 48(7). 721–728. 1 indexed citations
12.
Hagiwara, May, Thomas E. Delea, Richard H. Stanford, & David A. Stempel. (2010). Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy. Allergy and Asthma Proceedings. 31(3). 203–210. 11 indexed citations
13.
Delea, Thomas E., Simu K. Thomas, & May Hagiwara. (2010). The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinsonʼs Disease. CNS Drugs. 25(1). 53–66. 18 indexed citations
14.
Delea, Thomas E., Richard H. Stanford, May Hagiwara, & David A. Stempel. (2008). Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Current Medical Research and Opinion. 24(12). 3435–3442. 54 indexed citations
15.
Delea, Thomas E., May Hagiwara, Simu K. Thomas, et al.. (2007). Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. American Journal of Hematology. 83(4). 263–270. 28 indexed citations
16.
Vera‐Llonch, Montserrat, Gerry Oster, May Hagiwara, & Stephen T. Sonis. (2005). Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 106(2). 329–336. 290 indexed citations
17.
Delea, Thomas E., Richard H. Stanford, May Hagiwara, John Edelsberg, & Gerry Oster. (2004). Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. International Journal of Cardiology. 99(1). 117–124. 13 indexed citations
18.
Delea, Thomas E., Richard H. Stanford, May Hagiwara, John Edelsberg, & Gerry Oster. (2004). 821-5 Risks of death and hospitalization in heart failure patients receiving carvedilol versus metoprolol tartrate: A retrospective claims-based study. Journal of the American College of Cardiology. 43(5). A196–A196. 1 indexed citations
19.
Berger, Ariel, Ellen Dukes, Meredith Y. Smith, et al.. (2003). Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life. Journal of Pain and Symptom Management. 26(2). 723–730. 12 indexed citations
20.
Delea, Thomas E., May Hagiwara, John Edelsberg, & Gerry Oster. (2002). Exposure to glitazone antidiabetics and risk of heart failure among persons with type 2 diabetes: a retrospective population-based cohort analysis. Journal of the American College of Cardiology. 39. 184–184. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark Krasnik Breakdown of academic impact, for papers by Sheena Patel Breakdown of academic impact, for papers by Kelly W. Merriman Breakdown of academic impact, for papers by J. Green Breakdown of academic impact, for papers by C McLeod Breakdown of academic impact, for papers by L M Forrest Breakdown of academic impact, for papers by Beatriz Korc‐Grodzicki Breakdown of academic impact, for papers by Jonas Lundkvist Breakdown of academic impact, for papers by Young Eun Kwon Breakdown of academic impact, for papers by David R. Stather
Rankless by CCL
2026